NCT03589339 - NBTXR3 Activated by Radiotherapy for Patients with Advanced Cancers Treated with an Anti-PD-1 Therapy | Biotech Hunter

Enrollment

145

Participants

Timeline

Start Date

January 16, 2019

Primary Completion Date

April 30, 2027

Study Completion Date

May 30, 2028

Conditions

RadiotherapyImmunotherapyMicrosatellite Instability-High Solid Malignant TumourMetastasis from Malignant Tumor of LiverSquamous Cell Carcinoma of Head and NeckMetastasis from Malignant Tumor of CervixMetastatic Renal Cell CarcinomaMetastasis from Malignant Melanoma of Skin (disorder)Metastatic Triple-Negative Breast CarcinomaMetastatic NSCLCMetastasis from Malignant Tumor of Bladder (Disorder)

Interventions

DRUG

NBTXR3

Single intra Tumoral injection

RADIATION

SABR

Radiotherapy given as a definite number of fractions at the dose defined for each radiation field

DRUG

Nivolumab

Anti-PD-1 monotherapy

DRUG

Pembrolizumab

Anti-PD-1 monotherapy

Trial Locations (13)

11030

RECRUITING

Northwell Health, Manhasset

18015

RECRUITING

St Luke's University Health Network, Bethlehem

21287

ACTIVE_NOT_RECRUITING

Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Baltimore

27516

RECRUITING

University of North Carolina, School of Medicine, Chapel Hill

30308

RECRUITING

Emory University, Atlanta

33612

RECRUITING

Moffitt Cancer Center, Tampa

44718

RECRUITING

Gabrail Cancer Center, Canton

48201

RECRUITING

Karmanos Cancer Institute, Detroit

48202

ACTIVE_NOT_RECRUITING

Henry Ford Cancer Institute, Detroit

57104

RECRUITING

Sanford Cancer Center, Sioux Falls

60637

RECRUITING

University of Chicago Medical Center, Chicago

87505

RECRUITING

Christus St. Vincent Regional Cancer Center, Santa Fe

94158

RECRUITING

University of California San Francisco, San Francisco